Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 24 April 2012 | By Louise Zornoza
The Public Consultation - CP No. 26 - on proposed new criteria for establishing the priority review for registration of medicines opened on April 20 and comments may be submitted within 30 days.
The proposal would grant priority review according to a points system to products that reach at least 10 points.
The application for prioritization would have to be made electronically and ANVISA would have 75 days to decide on petitions for priority registration, 90 days for post-registration priority, and 45 days for prior consent for clinical research.
Read more:
ANVISA - Consulta Pública nº 26, de 11 de abril de 2012
Tags: Priority Review, CP No. 26, pharmaceutical, brazil, registration, drug